Allergic Conjunctivitis – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Allergic Conjunctivitis – Pipeline Review, H2 2020’, provides an overview of the Allergic Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis

– The report reviews pipeline therapeutics for Allergic Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Allergic Conjunctivitis therapeutics and enlists all their major and minor projects

– The report assesses Allergic Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Allergic Conjunctivitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Allergic Conjunctivitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ajanta Pharma Ltd

Aldeyra Therapeutics Inc

Alexion Pharmaceuticals Inc

Allakos Inc

Allergan Ltd

Clevexel Pharma SA

Dhp Korea Ltd

Eleusis Ltd

IACTA Pharmaceuticals Inc

iCo Therapeutics Inc

JW Pharmaceutical Corp

Kissei Pharmaceutical Co Ltd

Marinomed Biotech AG

Nanomerics Ltd

NicOx SA

Ocular Therapeutix Inc

OKYO Pharma Ltd

RAPT Therapeutics Inc

Re-Pharm Ltd

Sylentis SAU

Table of Contents

Table of Contents

Introduction

Allergic Conjunctivitis - Overview

Allergic Conjunctivitis - Therapeutics Development

Allergic Conjunctivitis - Therapeutics Assessment

Allergic Conjunctivitis - Companies Involved in Therapeutics Development

Allergic Conjunctivitis - Drug Profiles

Allergic Conjunctivitis - Dormant Projects

Allergic Conjunctivitis - Discontinued Products

Allergic Conjunctivitis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Allergic Conjunctivitis, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Allergic Conjunctivitis – Pipeline by Ajanta Pharma Ltd, H2 2020

Allergic Conjunctivitis – Pipeline by Aldeyra Therapeutics Inc, H2 2020

Allergic Conjunctivitis – Pipeline by Alexion Pharmaceuticals Inc, H2 2020

Allergic Conjunctivitis – Pipeline by Allakos Inc, H2 2020

Allergic Conjunctivitis – Pipeline by Allergan Ltd, H2 2020

Allergic Conjunctivitis – Pipeline by Clevexel Pharma SA, H2 2020

Allergic Conjunctivitis – Pipeline by Dhp Korea Ltd, H2 2020

Allergic Conjunctivitis – Pipeline by Eleusis Ltd, H2 2020

Allergic Conjunctivitis – Pipeline by IACTA Pharmaceuticals Inc, H2 2020

Allergic Conjunctivitis – Dormant Projects, H2 2020

Allergic Conjunctivitis – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Allergic Conjunctivitis, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports